A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Launched by EMERGENT BIOSOLUTIONS · Jun 15, 2018

Keywords

ClinConnect Summary

This clinical trial is designed to study the safety and effectiveness of a treatment called AIGIV (ANTHRASIL®) for patients who have inhalational anthrax, a serious illness caused by exposure to anthrax bacteria. The trial will only take place if there is a significant anthrax exposure event, and its main goal is to gather information about how well AIGIV works in helping patients recover from the illness, how safe it is, and to measure the levels of AIGIV and anthrax toxins in the patients' bodies.

To be eligible to participate, individuals must have confirmed or suspected inhalational anthrax linked to a known exposure scenario and must agree to receive treatment with AIGIV. There are no specific exclusions for participants in this study. If someone is involved in the trial, they can expect to receive AIGIV and be closely monitored for their health and recovery. This study is important because it aims to improve treatment options and understanding of inhalational anthrax in critical situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed or suspected inhalational anthrax linked to an identified broad exposure scenario.
• • Treatment with AIGIV.
• • Informed consent/assent (as applicable).
• Exclusion Criteria:
• • There are no exclusion criteria for subjects enrolling in this study.